Clinical trial to pioneer CBD viability studies for pet mobility

DENVER — Dixie Brands’ Therabis functional cannabidiol (CBD) supplements designed to improve mobility in dogs will be the basis of a clinical trial by the Veterinary Clinical Investigations Center at the University of Pennsylvania School of Veterinary Medicine (Penn Vet) to determine the effectiveness of CBD in treating osteoarthritis.  

Principal Investigator Dr. Kimberly Agnello will lead the double-blind study, which will include three groups of up to 20 dogs known to have inflammation caused by osteoarthritis. One group will be administered the proprietary Therabis formula, another will receive pure cannabidiol, and the third group will be given a placebo.

Agnello and her team will compare inflammation in the dogs’ front legs by using physical tests in order to quantify the effectiveness of each supplement.

“We are honored to have a Therabis product selected by the world-renowned experts at Penn Vet for their first major study of the effects of natural hemp

... read more at: